Profile: Aldeyra Therapeutics Inc (ALDX.OQ)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., incorporated on August 13, 2004, is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes.
The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency. NS2 is a small molecule designed to trap and thereby allow for the degradation of aldehydes. The Company has completed a double-masked, placebo-controlled, the United States-based Phase I clinical trial of approximately 0.25% and over 0.5% NS2 administered as an eye drop in approximately 50 healthy volunteers. It has completed a Phase IIa clinical trial, a Phase II clinical trial and a number of non-clinical and preclinical toxicity studies of NS2. In addition to the development of NS2, the Company focuses on the discovery and development of other aldehyde traps.
The Company competes with Aldea Pharmaceuticals, Novartis/Alcon, EyeGate Pharmaceuticals, Inc., Abbvie, Inc., Johnson & Johnson, UCB Inc. and UCB S.A., Amgen, Inc., Bristol-Myers Squibb Co. and Pfizer, Inc.
Aldeyra Therapeutics Inc
131 Hartwell Ave Ste 320
LEXINGTON MA 02421-3105